The clinical trial NCT03805841 [70] evaluated the ORR to tarloxotinib in NSCLC patients harboring insertion in exon 20 of the EGFR gene, activating mutation of HER2 or NRG1 fusion. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.